Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J. Cork, Peter D. Arkwright, Melinda Gooderham, Lisa A. Beck, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, John T. O'Malley, Naimish Patel, Megan Hardin, Neil M.H. Graham, Marcella Ruddy, Xian Sun, John D. Davis, Mohamed A. Kamal, Faisal A. KhokharDavid M. Weinreich, George D. Yancopoulos, Bethany Beazley, Ashish Bansal, Brad Shumel^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Entzündungsmedizin

Northwestern University
Washington University in St. Louis
Ludwig-Maximilians-Universität
University of Sheffield
University of Manchester
Queen's University, Kingston
University of Rochester Medical Center
University of Colorado School of Medicine
Peninsula Research Associates
Sanofi
Regeneron Pharmaceuticals, Inc.

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Fingerprint

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

INIS